Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Biopharmaceutical company Bristol-Myers Squibb (BMY) is performing on schedule, which is why I'm reiterating my buy rating for the company's shares, first recommended on June 1, 2009 at a price of $20.11. If you bought BMY in June, you're up about 24%.Look for a 6-8% revenue increase for BMY in 2010, boosted by revenue gains in key proprietary drugs, led by Plavix (for the prevention of stroke, heart attack, and vascular disease). Also look for impressive results from new products Orencia (for rheumatoid arthritis) and Sprycel (for leukemia); BMY's nutritional products also should register a good year. The First Call FY2009/FY2010 EPS estimates for BMY are $2.02 to $2.21.
Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, 
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
